Connect Biopharma Holdings Ltd
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
CNTB$0.68-9.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, 202 and
(In thousands, except par value and share amounts)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $38,345 | $78,232 |
| Short-term investments | 5,997 | 15,476 |
| Accounts receivable, net | 13 | 789 |
| Prepaid expenses and other current assets | 6,574 | 2,464 |
| Total current assets | 50,929 | 96,961 |
| Property and equipment, net | 3,808 | 4,048 |
| Right-of-use lease assets, net | 647 | 189 |
| Intangible assets, net | 45 | 53 |
| Other assets | 646 | 33 |
| Total assets | $56,075 | $101,284 |
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,964 | $342 |
| Accrued liabilities | 11,160 | 7,802 |
| Contract liabilities | 167 | 164 |
| Current lease liabilities | 322 | 154 |
| Total current liabilities | 13,613 | 8,462 |
| Non-current lease liabilities | 368 | 24 |
| Other non-current liabilities | 114 | 632 |
| Total liabilities | 14,095 | 9,118 |
| Commitments and contingencies (see Note 7) | ||
| Shareholders' equity: | ||
| Preferred shares, $0.000174 par value: 40,000,000 shares authorized; no shares issued or outstanding at December 31, 2025 and 2024 | — | — |
| Ordinary shares, $0.000174 par value; 400,000,000 shares authorized; 56,442,308 and 55,349,208 shares issued and outstanding at December 31, 2025 and 2024, respectively | 10 | 10 |
| Additional paid-in capital | 444,176 | 439,357 |
| Accumulated other comprehensive loss | (1,191) | (1,666) |
| Treasury shares | (180) | (180) |
| Accumulated deficit | (400,835) | (345,355) |
| Total shareholders' equity | 41,980 | 92,166 |
| Total liabilities and shareholders' equity | $56,075 | $101,284 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.